This review discusses the potential off-label use of oral selexipag in children and adolescents with PAH, including transitioning from IV therapies or as a third-line oral agent.
May inform off-label selexipag transitions in refractory pediatric PAH; leaves open need for dedicated trials.
We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH-targeted agent in children not responding well to dual PAH therapy.
No takes yet. Share an insight, caveat, or question.
Köestenberger et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: